肿瘤细胞治疗研究
英文原题：CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
CAR-T 细胞疗法在血液系统恶性肿瘤治疗中的成功，促使人们研究其在包括卵巢癌在内的实体瘤治疗中的潜力。
CAR-T 细胞治疗血液系统恶性肿瘤的成功，推动了其用于包括卵巢癌在内的实体瘤研究。卵巢癌免疫抑制性微环境一直是 CAR-T 应用的障碍，但目前多项早期临床试验正在评估靶向间皮素、叶酸受体 α、HER2、MUC16 和 B7H3 的 CAR-T 疗法。持续存在的挑战包括细胞因子相关毒性和“靶向肿瘤但同时损伤正常组织”的毒性；最常见不良事件包括细胞因子释放综合征、噬血细胞性淋巴组织细胞增多症/巨噬细胞活化样综合征（HLH/MAS）和神经毒性。本综述总结 CAR-T 治疗卵巢癌的现状并讨论未来方向。
The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier in their implementation, several early phase clinical trials are currently evaluating CAR-T cell therapies targeting mesothelin, folate receptor a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated and "on-target, off-tumor" toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions.
MEMBER ACCOUNT
登录成功会直接打开下一页。
